2025 Speakers

Aaron Hambrick

Aaron Hambrick

Sci Dir

Abbvie

Ali Benakila

Ali Benakila

Global Pharma Dx Strategy Leader

Roche

Andreas Jeromin, Stealth Mode - Market Access for CNS Therapeutics

Andreas Jeromin

CSO

New Diagnostic Company emerging from Stealth Mode

Brenda Hendron, LabCorp - Market Access for CNS Therapeutics

Brenda Hendron

VP, Market Access

LabCorp

Camilla Gomiero

Camilla Gomiero

VP

Engrail Therapeutics

Chad Bissell

Chad Bissell

Vice President, Drug Launch Services

Artia Solutions

Chuck Collins, The HSS Group - Market Access for CNS Therapeutics

Chuck Collins

President

The HSS Group

Damon Harrell

Damon Harrell

Vice President & General Manager, Psychiatry Francise

Formerly Alkermes

Elicia DeParolesa CVS Health - Market Access for CNS Therapeutics

Dr. Elicia DeParolesa, PharmD

Sr. Manager: Clinical Product Design, Strategy and Innovation

CVS Health

Glenn Harris

Glenn Harris

Director

Rainwater Charitable Foundation

Julio Rojas

Associate Professor of Neurology

UCSF

Kevin Lanzo, Pharmaka Clinical Consultant - Market Access for CNS Therapeutics

Kevin Lanzo

President

Pharmaka Clinical Consulting

Kristophe Diaz

Kristophe Diaz

CEO

Cure PSP

Laura Cohen -Market Access for CNS Therapeutics

Laura Cohen

Vice President, Alzheimer's Environment Shaping

Eli Lilly

Lori Englebert

Lori Englebert

Chief Commercial Officer

Compass Pathways

Martin Strebl-Bantillo - Market Access for CNS Therapeutics

Martin Strebl-Bantillo

Principal

Lumanity

Shawn Carlson, Roche - Market Access for CNS Therapeutics

Shawn Carlson

VP Market Access

Roche

Steve Beller, Neurolief - Market Access for CNS Therapeutics

Steve Beller

CCO

Neurolief

VIEW 2025 PROGRAM
REGISTER INTEREST
PARTNER